Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/1905
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | BARIANI, Giovanni M. | - |
dc.contributor.author | FERRARI, Anezka C. R. de Celis | - |
dc.contributor.author | HOFF, Paulo M. | - |
dc.contributor.author | KRZYZANOWSKA, Monika K. | - |
dc.contributor.author | RIECHELMANN, Rachel P. | - |
dc.date.accessioned | 2013-09-23T16:37:37Z | - |
dc.date.available | 2013-09-23T16:37:37Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | JOURNAL OF CLINICAL ONCOLOGY, v.31, n.18, p.2289-2295, 2013 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/1905 | - |
dc.description.abstract | Purpose Growing participation by industry in cancer research has resulted in increased reporting of conflicts of interest (COI). We aimed to test any association between authors' conclusions and self-reported COI or trial sponsorship in cancer studies. Methods Editorials and related phase III trials published in six clinical oncology journals in the last 3.5 years were analyzed independently by two investigators who classified study conclusions according to authors' endorsement of the experimental therapy. Logistic regression multivariable models were used to assess predictors of favorable conclusions of editorialists and of phase III authors. Results From January 2008 to October 2011, 1,485 articles were retrieved: 150 phase III trials and 150 editorials were eligible. Among the phase III trials, 82 (54.7%) had positive results, and 78 (52.0%) were entirely or partially funded by industry. Any COI were disclosed in 103 phase III trials (68.7%) and in 71 editorials (47.3%). Multivariable analysis showed that phase III trial results were the only significant predictor for a positive conclusion by trial authors (odds ratio [OR], 92.2; 95% CI, 19.7 to 431.6; P < .001). Sponsorship did not predict for positive conclusion by phase III authors (OR, 0.86; 95% CI, 0.3 to 2.5; P = .788). The only factor associated with positive conclusions by editorial authors was a positive conclusion by phase III trial authors (OR, 36.3; 95% CI, 6.8 to 194.2; P < .001). Conclusion The interpretation of recently published phase III cancer trials by their authors or by editorialists was not influenced by financial relationships or industry sponsorship. Increased awareness of COI policies may have led to more integrity in cancer research reporting. (C) 2013 by American Society of Clinical Oncology | - |
dc.language.iso | eng | - |
dc.publisher | AMER SOC CLINICAL ONCOLOGY | - |
dc.relation.ispartof | Journal of Clinical Oncology | - |
dc.rights | restrictedAccess | - |
dc.subject.other | clinical-trials | - |
dc.subject.other | economic-analyses | - |
dc.subject.other | financial relationships | - |
dc.subject.other | industry sponsorship | - |
dc.subject.other | cancer trials | - |
dc.subject.other | disclosure | - |
dc.subject.other | agreement | - |
dc.title | Self-Reported Conflicts of Interest of Authors, Trial Sponsorship, and the Interpretation of Editorials and Related Phase III Trials in Oncology | - |
dc.type | article | - |
dc.rights.holder | Copyright AMER SOC CLINICAL ONCOLOGY | - |
dc.identifier.doi | 10.1200/JCO.2012.46.6706 | - |
dc.identifier.pmid | 23630201 | - |
dc.subject.wos | Oncology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | KRZYZANOWSKA, Monika K.:Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada | - |
hcfmusp.description.beginpage | 2289 | - |
hcfmusp.description.endpage | 2295 | - |
hcfmusp.description.issue | 18 | - |
hcfmusp.description.volume | 31 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84882968646 | - |
hcfmusp.origem.id | WOS:000320446700014 | - |
hcfmusp.publisher.city | ALEXANDRIA | - |
hcfmusp.publisher.country | USA | - |
hcfmusp.relation.reference | Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454 | - |
hcfmusp.relation.reference | Booth CM, 2008, J CLIN ONCOL, V26, P5458, DOI 10.1200/JCO.2008.16.5456 | - |
hcfmusp.relation.reference | Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209 | - |
hcfmusp.relation.reference | Buchkowsky SS, 2004, ANN PHARMACOTHER, V38, P579, DOI 10.1345/aph.1D267 | - |
hcfmusp.relation.reference | COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256 | - |
hcfmusp.relation.reference | Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2 | - |
hcfmusp.relation.reference | Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453 | - |
hcfmusp.relation.reference | Gardner A, 2007, INT J HEALTH SERV, V37, P591, DOI 10.2190/33N9-23T2-K72T-2LLK | - |
hcfmusp.relation.reference | GEORGE B, 2007, J CLIN ONCOL, V25, pS355 | - |
hcfmusp.relation.reference | Hampson LA, 2007, J CLIN ONCOL, V25, P3609, DOI 10.1200/JCO.2006.09.3633 | - |
hcfmusp.relation.reference | Hartmann M, 2003, BRIT J CANCER, V89, P1405, DOI 10.1038/sj.bjc.6601308 | - |
hcfmusp.relation.reference | Jang S, 2011, AM J CLIN ONCOL-CANC, V34, P524, DOI 10.1097/COC.0b013e3181f4799b | - |
hcfmusp.relation.reference | Kesselheim AS, 2012, CANCER-AM CANCER SOC, V118, P188, DOI 10.1002/cncr.26237 | - |
hcfmusp.relation.reference | Knox KS, 2000, ANN ONCOL, V11, P1591, DOI 10.1023/A:1008309817708 | - |
hcfmusp.relation.reference | LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310 | - |
hcfmusp.relation.reference | Lerner TG, 2012, CONTEMP CLIN TRIALS, V33, P1019, DOI 10.1016/j.cct.2012.05.011 | - |
hcfmusp.relation.reference | Lexchin J, 2003, BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167 | - |
hcfmusp.relation.reference | Lexchin J, 2012, SCI ENG ETHICS, V18, P247, DOI 10.1007/s11948-011-9265-3 | - |
hcfmusp.relation.reference | Peppercorn J, 2007, CANCER, V109, P1239, DOI 10.1002/cncr.22528 | - |
hcfmusp.relation.reference | RIECHELMANN RP, J CLIN ONCOL S, V25, pS329 | - |
hcfmusp.relation.reference | Riechelmann RP, 2007, J CLIN ONCOL, V25, P4642, DOI 10.1200/JCO.2007.11.2482 | - |
hcfmusp.relation.reference | Rose SL, 2010, J CLIN ONCOL, V28, P1316, DOI 10.1200/JCO.2008.21.6606 | - |
hcfmusp.relation.reference | SCHNEIDER N, 2010, J PUBLIC HLTH, V18, P597, DOI 10.1007/s10389-010-0350-x | - |
hcfmusp.relation.reference | THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812 | - |
hcfmusp.relation.reference | Valachis A, 2012, J CLIN ONCOL, V30, P1316, DOI 10.1200/JCO.2011.38.6078 | - |
hcfmusp.relation.reference | *AM SOC CLIN ONC, ASCOS POL SAF REL IN | - |
hcfmusp.relation.reference | *BBC NEWS US CAN, BBC NEWS US CANADA | - |
hcfmusp.relation.reference | *J NAT CANC I FORM, FORMS CONFL INT | - |
hcfmusp.relation.reference | 1997, ANN INTERN MED, V126, P36 | - |
dc.description.index | MEDLINE | - |
hcfmusp.citation.scopus | 34 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - HC/InRad Artigos e Materiais de Revistas Científicas - LIM/24 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_BARIANI_Self_Reported_Conflicts_of_Interest_of_Authors_Trial_2013.PDF Restricted Access | publishedVersion (English) | 92.53 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.